Panacea Biotec Q1 Results FY27: Revenue Rs 199 crore, PAT Rs 2 Crore

Panacea Biotec Q1 results for FY27 were declared on August 13, 2026, covering the April to June 2026 quarter. Revenue came in at Rs 199 crore, up 19.72% year on year from Rs 166 crore. Net profit stood at Rs 2 crore on a consolidated basis. Gross profit was Rs -2 crore for the quarter.

The Panacea Biotec Q1 results analysis below covers financial highlights, key business drivers, FY27 outlook, and investor risks. The Nifty Pharma index reflects the broader Pharmaceuticals and Vaccines sector backdrop against which these results should be read.

Click Here – Get Free Investment Predictions

Panacea Biotec Q1 Results: Financial Highlights

Metric	Q1 FY27 (Jun 26)	Q1 FY26 (Jun 25)	YoY Change
Revenue	Rs 199 Cr	Rs 166 Cr	+19.72% YoY
Gross Profit	Rs -2 Cr	Rs -9 Cr	+76.70% YoY
Net Profit (PAT)	Rs 2 Cr	Rs 3 Cr	-44.44% YoY

Source: Company filing, August 13, 2026. Figures in Rs Crore. Consolidated basis.

Q1 FY27 Performance Analysis

Panacea Biotec Q1 results show revenue that expanded during the April to June 2026 period. Gross profit improved, pointing to better cost management during the quarter. Net profit of Rs 2 crore reflects a healthy earnings trajectory.

A detailed look at Panacea Biotec Q1 results reveals that revenue grew 19.72% year on year, while the consolidated numbers offer a group-level view of the company. Analysts will focus on margin trajectory and the outlook for the remaining quarters of FY27.

Investors assessing these quarterly results should also track working capital trends, operating leverage, and management commentary on FY27 guidance. Subsequent quarterly disclosures will help validate whether the trends visible in this print continue.

Check Live Financials on the Univest Screener

Key Business Factors This Quarter

Vaccine Revenue from Government and Export — This was a key driver this quarter. Its positive contribution supported the quarterly revenue trajectory. Investors should track changes in this area in subsequent disclosures.

Domestic Formulations Growth — This had a direct bearing on gross margins during the April to June 2026 period. Favourable movement here helped support the quarterly gross profit level. Management's approach will shape margin outcomes in the quarters ahead.

Operating Margin Recovery — This factor shaped the overall operating environment this quarter. Monitoring its trajectory will help investors anticipate directional changes in the next quarterly update.

Dividend Details

No interim dividend was announced as part of the quarterly results declared on August 13, 2026 for Panacea Biotec. Companies in the Pharmaceuticals and Vaccines sector typically declare dividends once a year alongside full-year results. Investors should monitor official BSE or NSE filings for any future payout updates.

FY27 Outlook for Panacea Biotec

Panacea Biotec Q1 results for FY27 establish a positive starting point for FY27. The Pharmaceuticals and Vaccines sector broadly faces steady conditions heading into H2 FY27, providing context for interpreting the April to June quarter print.

Investors using these Q1 FY27 results as a base for full-year projections should monitor whether revenue momentum and margin improvement continue into Q2 and Q3. Management commentary on capacity, order book, and pricing will be important inputs for refining full-year estimates.

Panacea Biotec Stock Performance After Q1 Results

Panacea Biotec's share price closed up at Rs 414.2, up 3.59% on August 13, 2026, the day the Q1 FY27 results were announced. The market received the results constructively. Stock movements on results day reflect immediate sentiment and may not represent the long-term investment picture.

Investors can track live price data and financial details on NSE (nseindia.com) and BSE (bseindia.com). Always verify current prices and official filings before any investment decision.

Download the Univest iOS App or Univest Android App to track Panacea Biotec's live share price.

Key Risks to Watch After the Q1 Results

Government Vaccine Procurement Timing

This risk could weigh on revenue or margins if it intensifies. Investors should track how management addresses this in upcoming quarterly disclosures.

Regulatory Compliance Risk

This represents a potential headwind for FY27. If it materialises, it could affect the earnings trajectory visible in recent quarterly numbers.

Competition in Vaccine Segment

This structural risk is shared with peers in the Pharmaceuticals and Vaccines space. It warrants monitoring as it can influence fair value and longer-term earnings potential.

Conclusion

Panacea Biotec Q1 results for FY27 highlight the challenges facing the company in the current environment. Net profit was under pressure year on year. The coming quarters will test whether recovery is underway. Investors reviewing Panacea Biotec Q1 results should consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Panacea Biotec Q1 Results

What were Panacea Biotec Q1 results for FY27?

Ans. Panacea Biotec Q1 results for FY27 show revenue of Rs 199 crore, up 19.72% year on year from Rs 166 crore and net profit of Rs 2 crore on a consolidated basis. Declared August 13, 2026.

When were the Q1 FY27 results declared for Panacea Biotec?

Ans. The Q1 FY27 results for Panacea Biotec were declared on August 13, 2026, covering the April to June 2026 quarter on a consolidated basis.

What was the revenue in Q1 FY27?

Ans. Revenue for the quarter was Rs 199 crore, up 19.72% year on year from Rs 166 crore. Refer to official BSE or NSE filings for complete financial data.

Did Panacea Biotec Q1 results include a dividend?

Ans. No interim dividend was included in the Q1 FY27 results announcement for Panacea Biotec. Dividends are typically declared with full-year results. Check official filings for updates.

How did the stock react to Q1 FY27 results?

Ans. The stock closed up at Rs 414.2, up 3.59% on August 13, 2026. Stock movements on results day reflect immediate sentiment and may not indicate long-term direction.

What are the key risks highlighted after Q1 FY27?

Ans. Key risks after Q1 FY27 include government vaccine procurement timing, regulatory compliance risk, and competition in vaccine segment. Track quarterly disclosures for updates on how these evolve.

What is the FY27 outlook based on Q1 FY27 performance?

Ans. Based on Q1 FY27 performance, FY27 full-year results will depend on sustaining revenue growth and expanding margins. The Pharmaceuticals and Vaccines sector environment and company execution will be the main drivers.

Where can I find the complete Q1 FY27 financial data for Panacea Biotec?

Ans. Panacea Biotec Q1 results are available on BSE (bseindia.com) and NSE (nseindia.com) filing portals. The Univest screener also provides a curated financial snapshot.